



PHARMACOLOGICAL EVALUATION OF NOOTROPIC AND NEUROPROTECTIVE ACTIVITY OF *SESBANIA GRANDIFLORA* EXTRACTS IN STREPTOZOTOCIN-INDUCED DIABETIC MODEL OF RATS

Jagadeeshwar Kolguri¹, Subhakara Raju Rapaka¹, Rajasekhar Reddy Alavala^{1,2*}, Koteswara Rao GSN¹, Shireesha Boyapati³ and Raghavendra Kumar Gunda⁴

¹K L College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, India-522502

²Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai- 400056, India

³Department of Pharmaceutical Chemistry, Telangana University, Nizamabad, Telangana, India-503322

⁴Department of Pharmaceutical Sciences, Vignan's Foundation for Science, Technology and Research, Vadlamudi, Guntur, Andhra Pradesh, India-522213

Background: Diabetes Mellitus (DM) is a multifactorial disorder and is frequently correlated with chronic problems associated with various major organs. In recent times, there has been some correlations reported about the neurological complications of DM, such as cognitive impairment, vascular dementia, stroke, or depression. and observed that the brain tissue of the diabetic patients with hyperglycemia have shown injury at various locations with a varied profile of micro and macrostructural changes, which leads to the neurodegeneration, neuro-vascular deterioration, neuro-inflammation, and progressive cognition decline. **Aim:** The current study assesses memory enhancing activity of *Sesbania grandiflora* (SG) extracts in streptozotocin (STZ)-induced diabetic model in rat. **Methods:** The extracts (petroleum ether, ethyl acetate and methanol) were analyzed for acute toxicity and later its neuroprotective and memory enhancing activity in the selected rat model. STZ (55 mg/kg) injection was administered intraperitoneally to the animals to induce memory impairment. SG extracts were administered for 70 days after confirming STZ-induced dementia to detect its beneficial effect. To know the memory function the animals were subjected to Y-maze and Morris water maze test. After the tests, the animals were sacrificed and performed cholinergic function and oxidative stress with the brain tissue. **Results:** It was observed that STZ caused significant memory impairment, which was significantly reversed by methanolic extract with 100 and 200 mg/kg. It was found that the cholinergic dysfunction, rise in lipid peroxidation levels were significantly ($p < 0.001$) reduced. In the diabetic induced group, it was identified that there was a radical reduction of glutathione, superoxide dismutase, and catalase activities than the control group animals. **Conclusion:** The current investigation established that SG leaf extracts improve the memory by enhancing the cholinergic transmission and reducing the oxidative stress in the brain of diabetic rats.

Keywords: Diabetes, dementia, cholinergic dysfunction, oxidative stress and *Sesbania grandiflora*.

INTRODUCTION

Alzheimer's disease (AD) is considered as the primary cause of dementia in people with age 65 and above, and it appears to be more prevalent in every decade of life¹. World Health

Organization says that it is an age-associated disease and was estimated to affect 1 in 85 people by 2050. It was reported to affect 450 million people around the globe irrespective of the geography^{2&3}. It affects the neuronal cells in the specific brain region, producing difficulties

with memory, rare behavior, struggle in thinking⁴, and finally leads to death⁵. The cholinergic neuron transmission was found to be affected in the brain leads to the significant role in learning and memory^{6&7}.

Diabetes has been approved as one of the quickly emerging global health concern in the 21st Century. It was estimated that around 463 million adults of age between 20 and 79 years are presently living with DM. The countries such as China, India and the United States are likely to stay on the most prevalent countries in 2030 also. In India, it was anticipated that the number of diabetes affected people to increase from 77 million (2019) to 101 million by 2030 and further to 134 million by the end of 2045. It is predicted that management cost of treatment of DM will be around \$825 billion by 2030 and will reach \$845 billion by 2045^{8&9}. In recent times, there has been some correlations reported about the neurological complications of DM, such as cognitive impairment, vascular dementia, stroke, or depression, though the mechanisms associated have not been completely established¹⁰. It's been observed that the brain tissue of the diabetic patients with controlled or uncontrolled hyperglycemia have shown injury at various locations with a varied profile of micro and macrostructural changes, which leads to the neurodegeneration, neurovascular deterioration, neuro-inflammation, and progressive cognition decline¹¹. This establishes the correlation between the DM and AD associated clinical symptoms in the patients affected with DM.

Sesbania grandiflora Linn belongs to the family of Fabaceae, it is known as hummingbird tree or scarlet wisteria. It is majorly found in India or Southeast Asian regions, and it requires hot and humid areas for cultivation initially. The *Sesbania grandiflora* plantations were cultivated in Krishnagiri district, Tamil Nadu state in the month of October¹². *Sesbania grandiflora* plant extracts of root, bark, leaves, and flowers proved to possess various pharmacological activities like anticancer¹³, antioxidant¹⁴, cardioprotective¹⁵, antiurolithiatic¹⁶, hepatoprotective¹⁷, anxiolytic & anticonvulsive¹⁸, anti-inflammatory & anti-arthritis¹⁹, antiulcer²⁰ and antidiabetic activities²¹.

Phytoconstituents from natural origin either isolated compounds or whole extracts have been extensively evaluated in metabolic

disorders and numerous compounds have exhibited antioxidant, anti-inflammatory and neuroprotective properties. The current work is aimed to explore the natural compounds obtained from the *Sesbania grandiflora* plant for neuroprotective activities, by considering the various therapeutic targets: inflammation, oxidative stress, vascular damage, or cognitive impairment.

MATERIALS AND METHODS

Plant Materials

Sesbania grandiflora Linn (SGL) leaves were collected in the month of February 2020 from Chittoor district, Andhra Pradesh, India.

Drugs & Chemicals

Piracetam obtained from Alkem Laboratories Ltd, Metformin as gift sample from Cipla Pharmaceuticals, Diagnostic Kits purchased from Bio Lab, India, and Streptozotocin were bought from Sigma Aldrich, India.

Selection of Animals

From mahaveer enterprises, selected wistar rats of 150 to 200 gm and albino mice of 20 to 25 gm of both sexes were procured and maintained under standard laboratory conditions (25±1°C, 55±10% & 12 hrs light to dark cycle) and fed with usual pellet diet and water *ad libitum*. The experimental procedures were followed after getting the ethical approvals from the institute with reference number CPCSEA/IAEC/VCOP/19/8/12.

Preparation of the Extracts

Sesbania grandiflora leaves collected and washed, sliced to small pieces, exposed to shade-drying, pulverized, and extracted with increasing polarity from petroleum ether (**PE**), ethyl acetate (**EA**) and methyl alcohol (**MA**) for 12 h at 50°C using a Soxhlet apparatus. The resultant extract was transformed into 2% sodium carboxymethyl cellulose (CMC) mixture employing mortar and pestle for further studies.

Phytochemical Investigation

Selected plant extracts were carried out for evaporation to get residue and adding dilute Hydrochloric acid to it. Consequently unsteady and then filtered. This filtrate used for carrying

out the identification tests for numerous phytochemical constituents²².

Acute toxicity study

As per the OECD-423 acute toxicity test was performed by using three mice for each step. The doses of 5, 50, 300, and 2000 mg/kg per oral route were chosen as four fixed-dose levels²³.

Grouping of Animals

Total 60 wistar rats (100-120 gm) existed arbitrarily split up into ten distinct groups, each group having 6 rats and treated with following intervention for 71 consecutive days (Table 1).

Group I, consisting of 6 rats which was given with 2% solution of Sodium CMC orally and acting as a control group. To the Group II animals, along with 2% Sodium CMC, Streptozotocin also was administered orally, which serves as disease control group. Group III animals were used for standard drug Metformin treatment (oral administration) followed by Streptozotocin administration. Group IV was given with Piracetam (oral administration) along with Streptozotocin. Group V and VI received the PEESGL 100 & 200 mg/kg respectively followed by Streptozotocin. Group VII and VIII were given with EAESGL 100 & 200 mg/kg respectively and after 70 days of Streptozotocin administration. Group IX and X received MAESGL 100 & 200 mg/kg was dispensed orally 70 days followed by Streptozotocin²⁴.

Experimental Procedure

Induction of Diabetes

For diabetes induction the overnight fasting animals were divided into 10 groups (n=6), 55 mg/kg of streptozotocin (STZ) (intraperitoneal) was chosen to induce disease to the experimental animals. The glucose levels in blood were estimated after 48 hrs by the GOD-POD method the blood glucose level greater than 250 mg/dl of reflected as diabetic^{25&26}.

Spontaneous Alteration Behavior in Y-Maze Test

The Continuous impulsive alternation behaviour of rats was observed by using Y-maze test. It made up of plastic with three arms of dimensions $36 \times 7 \times 13$ cm spreading like a trigonal planar structure from the central core with 120° each. Every subject was kept at the corner of one arm and permitted to travel easily from end to end in the Y maze for the period of 8 min. Entry of arm was clear when the 4 paws into one arm. The entry into the arm confirmed visually and noted. If the animal made numerous entries into any arm (A, B, C) was considered as an alternation on overlapping triplet sets. The spontaneous alternation percentage was estimated on day 71 & 75 by the below equation²⁷:

$$\% \text{ of Alternation} = \left[\frac{\text{(number of alternation)}}{\text{(total arm entries-2)}} \right] \times 100.$$

Morris Water Maze

Wistar rats were accustomed to find immersed stage (6.5 cm diameter and 1 cm below the water surface) in a rounded pool (60 cm diameter & 30 cm height) occupied by turbidity water. Outside visual hints were situated over the pool to navigate the animals in such a predetermined manner. The immersed platform was immovable at SW (south-west) path. Head start varied between NE (north-east), SE (south-east), and NW (north-west) path in a pseudo-random style. Every animal was positioned in the water in front of the wall of the pool and supported to swim to reach the platform for about 60s. Locating the platform was distinct as existence intelligent to remain on it for minimum 2s; rat that cross over the platform devoid of discontinuing (leaping instantaneously back into the water) were allowed to swim till the end of the trail.

When the rat unsuccessful in discovering the platform in allocated time, the rat was manually placed onto the platform and considered as a latent time of 60s. After each trail, the rats were dehydrated with cloth and allowed to rest for 5 minutes and allowed for next trail.

Table 1: Grouping of animals for the experimentation.

S. No	Group	Treatment	Dose (mg/kg)	No of rats
1	Group I	Control	NIL	6
2	Group II	Streptozotocin	55	6
3	Group III	Metformin+Streptozotocin	10	6
4	Group IV	Piracetam+Streptozotocin	5	6
5	Group V	PEESGL+Streptozotocin	100	6
6	Group VI	PEESGL+Streptozotocin	200	6
7	Group VII	EAESGL+Streptozotocin	100	6
8	Group VIII	EAESGL+Streptozotocin	200	6
9	Group IX	MAESGL+Streptozotocin	100	6
10	Group X	MAESGL+Streptozotocin	200	6

PEESGL: Petroleum Ether Extract of SGL Leaf; **EAESGL:** Ethyl Acetate Extract of SGL Leaf; **MAESGL:** Methyl Alcohol Extract of SGL Leaf .

Rats executed four successive trials per day completed a 4-day training period. The time taking to reach the target is the escape latency for each rat was documented manually. On the last day a probe trail was approved. Each rat underway at NE can swim easily for 60s. memory retaining was determined by measuring the time to reach the target platform²⁸.

Neurotoxicity Studies

For neurotoxicity studies experimental animals were sacrificed and brain was removed and weighed. For brain homogenization, 20 mg of the brain tissue was suspended per ml of cold pH 7.4 phosphate buffer and centrifugation was done at 800 rpm for 5 mins at 4 °C to split the nuclear fragments and again performed the centrifugation at 1050 rpm for 20 minutes at 4 °C to get the supernatant. This supernatant was utilized for biochemical parameters estimation.

Estimation of Acetylcholinesterase (AChE)

Ellman's method was employed for the estimation of neurochemical (AChE) assessment. 0.4 ml of supernatant layer of the brain homogenate, 2.6 ml of phosphate buffer (pH 8) and 100 µL of DTNB (5,5'-dithiobis-(2-nitrobenzoic acid)) and then the absorbance was measured by a spectrophotometer at 412 nm wavelength. 20 µL acetylthiocholine-iodide was taken as substrate for the enzyme and noted the alterations in absorbance for a period of 10 mins at intervals of 2 mins. Difference in the absorbance per min was dignified and

acetylcholinesterase activity was stated as µM/l/min/gm of tissue²⁹.

Assessment of anti-oxidant activity of plant extracts

According to method of Wills the lipid peroxidation of plant extracts was evaluated. The development of malondialdehyde (MDA) is critical for thiobarbituric acid reactive substance levels and it is quantified in MDA/mg of the protein³⁰.

Total nitric oxide levels

The 500 µl of Greiss reagent was added to supernatant liquid (100 µl) and the resultant solution absorbance was estimated at 546 nm. The amount of nitrite was measured by using sodium nitrite standard curve and it is stated as ng/mg of the protein³¹.

Superoxide dismutase (SOD) levels

According to the method of Kono, SOD levels were assessed and for the supernatant layer (100 µl), added the sodium carbonate (1ml), of nitroblutetrazolin (0.4 ml) and of ethylene diamine tetra acetic acid (0.2 ml) and the corresponding absorbance was determined at 560 nm and is expressed in µg/mg of protein³².

Catalase (CAT) levels

According to the method of Claiborne the CAT levels were assessed. A supernatant of 100 µl added with 1.9 ml of phosphate buffer measure the absorbance at 240 nm and it is specified as µg/mg of protein³³.

Glutathione (GSH) levels

According to the method of Jollow the GSH levels were assessed. The GSH levels were estimated spectrophotometrically at 412 nm and stated as ng/mg of protein³⁴.

Results Analysis

The data were articulated in Mean \pm SD. The result was evaluated through one-way ANOVA and followed by Tukey's comparison tests with GraphPad Prism 5.0 and p value < 0.05 must be deliberated as significant.

RESULTS AND DISCUSSION

Result

Acute toxicity studies

Up to 2000 mg/kg of *S. grandiflora* extracts did not show any death or illness were perceived in various doses for 14 days. Hence, the median lethal dose (LD₅₀) of SG was greater than 2000 mg/kg. The results of acute toxicity study showed no clinical signs of toxicity and mortality in the SG treated animals even after administration of 2000 mg/kg dose. Hence, as per OECD guidelines lethal dose was assigned to be more than 2000 mg/kg. 1/20th and 1/10th of this lethal dose (i.e. 100 mg/kg and 200 mg/kg) were taken as effective doses for the study.

Preliminary Phytochemical Analysis

The phytochemical screening of leaf extracts of *S. grandiflora* was investigated for the secondary metabolites such as alkaloids, glycosides, flavonoids, tannins, steroids, terpenoids, carbohydrates and proteins. The preliminary phytochemicals recognized the presence and absence showed in Table-2.

Table 2: The Qualitative Determination of Phytochemicals in Pet Ether, Ethyl acetate and Methanol of *S. grandiflora*.

Phytochemical	Pet ether	Ethyl acetate	Methanol
Alkaloids	+	+	+
Glycosides	-	+	+
Flavonoids	-	+	+
Tannins	-	+	+
Steroids	+	+	+
Tri Terpenoids	-	-	-
Protein	-	+	+
Carbohydrates	+	+	+

Nootropic Activity

Y-Maze Test

The outcomes obtained for the effect of *S. grandiflora* leaf extracts for the percentage of spontaneous alternation in Y-maze are showed in Figure 1. The control group was compared with the disease control group (STZ-induced) and induction of amnesia was significantly established (^{a***}p < 0.001). After the administration with *S. grandiflora*, assessed against disease control group **Piracetam** (5mg/kg), **EASGL** (200 mg/kg) **MASGL** (100 and 200 mg/kg) fed animals demonstrated a substantial (^{b***}p < 0.001) improvement in memory and learning ability on Day 71 and 75.

Morris Water Maze Test

Transfer Latency of *S. grandiflora* leaf extracts on tested animals through morris water maze was showed in Figure 2. The transfer latency of disease control group (STZ-induced) is significantly (^{a***}p < 0.001) increased in contrast to the control group. Once treatment with *S. grandiflora*, compared with disease control group Piracetam (5mg/kg), EASGL (100 and 200 mg/kg) MASGL (100 and 200 mg/kg) treated animals showed a significant (^{b***}p < 0.001) reduction in transfer latency on Day 75. On day 71 also shows significant decrease in transfer latency were observed.

Estimation of Acetylcholinesterase (AChE)

The action on AChE existed significantly (^{b***}p < 0.001) decreased by Piracetam, EASGL and MASGL with the doses of 100 and 200 mg/kg of when compared with disease control group (Figure 3).

Assessment of anti-oxidant activity of plant extracts

The outcomes of lipid peroxidation shown in STZ administered group stated significantly rise in the levels of MDA (^{a***}p < 0.001) in contrast to the control group. *S. grandiflora* treatment, EASGL (100 and 200 mg/kg) significantly inhibited (^{b**}p < 0.01), whereas MASGL (100 and 200 mg/kg), Metformin (10 mg/kg) and Piracetam (5 mg/kg) treated animals showed more significantly (^{b***}p < 0.001) inhibited the MDA level in diabetic rats (Figure 4).




Fig. 1: Spontaneous alterations of *S. grandiflora* extracts in STZ induced amnesia Rats.




Fig. 2: Transfer latency of *S. grandiflora* extracts in STZ induced amnesia Rats.




Fig. 3: Effect of *S. grandiflora* Acetyl choline esterase activity in STZ rats.




Fig. 4: TBARS levels in brain tissue.

Effect on nitrosative stress

Levels of Nitrite were considerably ($a^{***}p < 0.001$) raised in the brain tissue of STZ administered rats when matched with control group. *S. grandiflora* extract of EASGL administration in 100 and 200 mg/kg doses substantially inhibited ($b^{**}p < 0.01$), whereas MASGL (100 and 200 mg/kg), Metformin (10 mg/kg) and Piracetam (5 mg/kg) treated rats displayed more significant ($b^{***}p < 0.001$) effect on the NO level in inhibition in diabetic rats (Figure 5).

Catalase enzyme level in the brain tissue

Estimation of brain CAT activities significantly ($a^{***}p < 0.001$) diminution in the in diabetic induced group when compared with than the control, while *S. grandiflora* treatment, EASGL (200 mg/kg), MASGL (100 and 200 mg/kg), Metformin (10 mg/kg) and Piracetam (5 mg/kg) treated rats demonstrated more significantly ($b^{***}p < 0.001$) increase the CAT in diabetic rats (Figure 6).

SOD effect in the brain tissue

The SOD formation was considerably decreased in the brain tissue of the STZ treated rat ($a^{***}p < 0.001$) when compared with control. Administration of *S. grandiflora* extracts of EASGL (200 mg/kg), MASGL (100 and 200 mg/kg), Metformin and Piracetam treated rats indicated more significantly ($b^{***}p < 0.001$) increase the SOD effect in diabetic rats (Figure 7).

GSH level in the brain tissue:

Assessment of GSH levels showed a considerable reduction in the STZ group compared to the control rat ($a^{***}p < 0.001$). Administration of *S. grandiflora*, EASGL (200 mg/kg), MASGL (100 and 200 mg/kg), Metformin and Piracetam treated rats demonstrated more significantly ($b^{***}p < 0.001$) increase the GSH effect in diabetic rats (Figure 8).




Fig. 5: Total Nitrite levels in brain tissue.




Fig. 6: Catalase enzyme level in the brain tissue.




Fig. 7: SOD effect in the brain tissue.




Fig. 8: Glutathione (GSH) level in the brain tissue.

Discussion

For Alzheimer's disease, currently there is no treatment available and the present medications existing is only palliative treatment with limited efficacy. The application of alternative medication such as herbal extract produces a broad approach to the management of neurological conditions such as AD³⁵. Truly, numerous reports of scientific experiments have indicated that the consumption of several remedial plants and the extracts of bioactive elements for the cure of AD. While the precise molecular mechanism is still not known, the phytochemical evaluation of the various parts of the plants must revealed the existence of numerous valuable secondary metabolites, that display an extensive range of pharmacodynamic actions, including anti-cholinesterase, anti-inflammatory, hypolipidemic and antioxidant properties³⁶. The current study deals with the *S. grandiflora* leaf extracts were given for 70 days to the animals and the neuroprotective action in methanol-induced animal model of cognitive impairment

and corresponding oxidative stress were investigated.

The current investigation analyzed the impacts of *S. grandiflora* solvent extracts treatment on memory loss, oxidative stress, and cholinergic transmission impairment in chemically induced (*i.e.*, STZ) animal model of diabetes in mice. Previous investigations have proposed that DM is associated with various neurological impairments in the focal sensory network³⁷ like cognition and learning capabilities³⁸. STZ can induce type 1 or type 2 diabetes depending on the concentration used. In this present investigation, the intension is to get not exclusively the diabetes type of model, and to those additional defects in memory was also considered³⁹. Chemically STZ is a glucosamine-nitrosourea derivative, have got anti-microbial properties and found to be poisonous to the pancreatic β cells and is used to produce exploratory diabetic condition in experimental animals. When STZ administered through the intraperitoneal routes, it creates cognition impairment and enhances cerebral masses of Amyloid β and tau protein⁴⁰. STZ

injection can produce the AD like pathophysiological condition in animal brain by causing the neuroinflammation and oxidative stress, which is the suitable experimental model⁴¹. Moreover, the treatment of STZ causes the brain cells to become insulin-resistant, which produces the normal dementia like condition with loss of memory, progressive cholinergic deficiencies, carbohydrate hypometabolism, stress due to reactive oxygen species (ROS), and finally neurodegeneration^{42&43}.

There are various reports of the neuroprotective properties of various phytoconstituents helps in the management of neurological disorders along with associated mood disorders and memory related problems. Results of present study showed significant improvement in spatial reference memory and transfer latency, suggesting of nootropic activity of SGL extracts in diabetes induced cognitive decline models. Oxidative stress in brain generates oxygen radical like superoxide anion, hydroxyl radical, and hydrogenperoxide, which act on polyunsaturated fatty acids in brain, thereby propagating the lipid peroxidation. The major antioxidant and oxidative free radical scavenging enzyme like GSH, SOD and catalase plays an important role to reduce oxidative stress in brain. Oxidative damage to various brain regions constitutes the long-term complications, morphological abnormalities and memory impairments. In the present study, TBARS levels were significantly increased ($P < 0.001$) whereas GSH, SOD and CAT levels were markedly reduced in the brains of diabetic control. Treatment with SGL extracts significantly reduced the levels of TBARS, whereas GSH, SOD and CAT levels were increased. Therefore, SGL might have protective effect against diabetes induced cognitive decline due to reduced oxidative stress. The antioxidant properties of SGL might help to ameliorate the cognitive dysfunction in diabetic animals.

The neurotransmitter acetylcholine is degraded by the enzyme AChE. Therefore, the use of AChE inhibitors is the most effective pharmacological approach for the symptomatic treatment of AD. We observed a significant rise in AChE activity in the brain of diabetic rats. Treatment with MM attenuated increase in AChE activity in the brain of diabetic animals. Hence, SGL extracts treatment ameliorated cognitive decline, cholinergic dysfunction,

reduced oxidative stress, and NO in the diabetic animals which may find clinical application in treating neuronal deficit in the diabetic patients. STZ causes the oxidative stress by fundamentally expanding the MDA levels and diminishing the GSH level. Besides, the nitrite levels in the brains of control group are fundamentally increased. This increment in the oxidative pressure might be expected to uncontrolled hyperglycemia occurrence in brain after STZ injection. The brain tissue of STZ treated animal are referred to show diminished glucose consumption when contrasted with the control group animals, prompting hyperglycemic condition⁴³. Due to the enhanced extracellular levels of glucose may be considered to produce the glucose auto-oxidation and bringing about creation of advanced glycation end products. Therefore, due to the high oxidative stress, enhanced free radicals caused the increase in Nitrite level⁴⁴. Hyperglycemia incites up-regulation of iNOS and equal increment in production of superoxide triggers the formation of pro-oxidant, peroxynitrite, which amplifies the oxidative strain⁴⁵.

The treatment of STZ fundamentally increased the MDA levels and the corresponding series of lipid peroxidation in the animal brain. Here, it was also observed that the rise in lipid peroxidation is correlated with the reduced levels or activity of the antioxidants like glutathione peroxidase and catalase, it was evident in the current study. These results are aligned with the previous studies, which recommend that the antioxidant compound capacities diminished in the brain during persistent diabetic neuropathy⁴⁶. The diabetic induced animal models, shown reduced synaptic versatility and obstructed exhibitions in behavioral learning tasks, and a decrease in diabetic animal performance, for example, Morris water maze and Y-maze⁴⁷. From the above result it was concluded that diabetes induced cognitive decline was improved by the treatment with SGL leaf extracts in rats and further investigation is needed to know the exact mechanism of cognition for developing lead compounds and to overcome the limitations of the current work.

Conclusion

In the Current investigation, the treatment of extracts of *S. grandiflora*, to the diabetic animals, enhanced the spatial memory and

condition avoidance memory. It was observed that there is an improvement in the memory augmentation after the STZ induced disorder condition with the plant extract treatment. Whereas the vehicle treated animal group have shown the memory deficit even after 20 days of treatment. In addition to that we have studied the impact of *S. grandiflora* on spatial navigation memory in diabetic induced mice by cross-arm maze. We observed that diabetes could altogether reduce the real alternation percent as an index; nonetheless, oxidative stress might add to spatial navigation memory in hyperglycemia condition. In this, we found that *S. grandiflora* extracts could increase the alternation percent in the cross-maze test, but no alteration in locomotor activity. Treatment with *S. grandiflora* extended the locomotor movement and the alternation percent in diabetic rats; though, *S. grandiflora* increased the alternation percent yet didn't modify the locomotor action in non-diabetic rat. This logical inconsistency shows that increasing impact of *S. grandiflora* on actual alternation score couldn't be an outcome from the locomotors action is lower in diabetic animals. Moreover, the data from the Morris water maize test additionally affirm the impact of *S. grandiflora* enhancing effect on increasing the spatial memory in diabetic and non-diabetic animals.

Acknowledgements

The authors wanted to thank the Registrar, Koneru Lakshmaiah Education Foundation for providing the necessary facilities for the smooth conduction of the proposed research work.

Conflict of Interest

Authors declare no conflict of interest

REFERENCES

1. P. J. Ghumatkar, S. P. Patil, P. D. Jain, R. M. Tambe, and S. Sathaye, "Nootropic, neuroprotective and neurotrophic effects of phloretin in scopolamine induced amnesia in mice", *Pharmacol Biochem Behav*, 135, 182–191 (2015)
2. R. Gupta, and H. K. Singh, "Nootropic potential of *Alternanthera sessilis* and *Clerodendrum infortunatum* leaves on mice", *Asian Pacific J Trop Dis*, 2 (Suppl1), 465-470 (2012).
3. L. Shivakumar, S. T. Gouda, N. V. Rao, Shalam, and V. Richa, "Evaluation of nootropic activity of polyherbal formulation Sr-105", *Int Res J Pharm*, 2(4), 101-107 (2011).
4. P. D. Kulkarni, M. M. Ghaisas, N. D. Chivate, and P. S. Sankpal, "Memory enhancing activity of *Cissampelos pariera* in mice", *Int J Pharm Pharm Sci*, 3(2), 206-211 (2011).
5. K Kaur, R Kaur, and M Kaur, "Recent advances in Alzheimer's disease: causes and treatment", *Int J Pharm Pharm Sci*, 8(2), 8-15 (2016).
6. T. Nabeshima, "Behavioral aspects of cholinergic transmission: role of basal forebrain cholinergic system in learning and memory", *Prog Brain Res*, 98, 405-411 (1993).
7. F. Khakpai, M. Nasehi, A. Haeri-Rohani, A. Eidi, and M. R. Zarrindast, "Scopolamine induced memory impairment; possible involvement of NMDA receptor mechanisms of dorsal hippocampus and/or septum", *Behav Brain Res*, 231(1), 1-10 (2012).
8. Diabetes a major health challenge for India.2021.
<https://www.cnbctv18.com/views/diabetes-a-major-health-challenge-for-india-8330931.htm> (accessed on 20 February 2021)
9. World Health Organization. Diabetes. Available online:
<https://www.who.int/diabetes/en/> (accessed on 30 April 2019).
10. M. W. Strachan, R. M. Reynolds, B. M. Frier, R. J. Mitchell, and J. F. Price, "The role of metabolic derangements and glucocorticoid excess in the etiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies", *Diabetes Obesity Metab*, 11(5), 407–414 (2009).
11. C. Moran, R. Beare, W. Wang, M. Callisaya, and V. Srikanth, "Alzheimer's Disease Neuroimaging Initiative (ADNI). Type 2 diabetes mellitus, brain atrophy, and cognitive decline", *Neurology*, 92(8), e823–e830 (2019).

12. *Sesbania grandiflora* (L.) POIRET, Biodiversity in Medicinal and Aromatic Plants in India. <http://www.impgc.com/test.php?id=Sesbania%20grandiflora/> [(Accessed on 30 May 2010)]
13. S. Sreelatha, P. R. Padma, E. Umasankari, "Evaluation of anticancer activity of ethanol extract of *Sesbania grandiflora* (Agati Sesban) against Ehrlich ascites carcinoma in Swiss albino mice", *J Ethnopharmacol*, 134 (1), 984-987 (2011).
14. T. Ramesh, C. Sureka, S. Bhuvana, and V. Hazeena Begum, "*Sesbania grandiflora* diminishes oxidative stress and ameliorates antioxidant capacity in liver and kidney of rats exposed to cigarette smoke", *J Physiol Pharmacol*, 61 (4), 467-476 (2010).
15. T. Ramesh, R. Mahesh, C. Sureka, and V. H. Begum, "Cardioprotective effects of *Sesbania grandiflora* in cigarette smoke-exposed rats", *J Cardiovasc Pharmacol*, 52(4), 338-343 (2008)
16. S. Doddola, H. Pasupulati, B. Koganti, and K.V. Prasad, "Evaluation of *Sesbania grandiflora* for antiurolithiatic and antioxidant properties", *J Nat Med*, 62 (3), 300-307 (2008)
17. L. Pari, and A. Uma, "Protective effect of *Sesbania grandiflora* against erythromycin estolate-induced hepatotoxicity", *Therapie*, 58 (5), 439-443 (2003).
18. V. S. Kasture, and V. K. Deshmukh, "Anxiolytic and anticonvulsive activity of *Sesbania grandiflora* leaves in experimental animals", *Phytotherapy Research*, 16 (5), 455-460 (2002)
19. R. B. Patil, B. K. Nanjwade, and F. V. Manvi, "Antiinflammatory and antiarthritic activity of *Sesbania grandiflora* and *Sesbania sesban* Bark in rats", *Adv. Pharmacol. Toxicol.*, 12 (1), 61-70 (2011).
20. Jayme Antônio Aboin Sertié, Guiomar Wiezel, Ricardo Gomide Woisky, José Carlos and Tavares "Carvalho, Antiulcer activity of the ethanol extract of *Sesbania grandiflora*", *Braz J Pharma Sci*, 37 (1), 107-112 (2001).
21. Rajit Kumar, Suresh Janadri, Santosh Kumar, D. R. Dhanajaya, and Shivakumar Swamy, "Evaluation of antidiabetic activity of alcoholic extract of flower *Sesbania grandiflora* in alloxan induced diabetic rats", *Asian J Pharm & Pharmacol*, 1(1), 21-26 (2015).
22. K. R. Khandelwal. "Practical pharmacognosy, 19th ed, Pune, Nirali Prakashan, (2008).
23. R. P. Gujjeti, and E. Mamidala, "Phytochemical screening and thin layer chromatographic studies of *Aerva lanata* root extract", *Inter J Innov Res Sci Eng Tech*, 2(10), 5725-5730(2013).
24. K. A. Talpate, U. A. Bhosale, M. R. Zambare, and R. S. Somani, "Neuroprotective and nootropic activity of *Clitorea ternatea* Linn (Fabaceae) leaves on diabetes induced cognitive decline in experimental animals", *J Pharm Bioall Sci*, 6(1), 48-55 (2014).
25. P. Trinder, "Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor", *Ann Clin Biochem*, 6, 24-27 (1969).
26. G. Raghavan, V. Madhavan, C. Rao, V. Kumar, A. K. Rawat, and P. Pushpangadan, "Action of *Asparagus racemosus* against streptozotocin-induced oxidative stress", *J Nat Prod Sci*, 10(4), 177-181 (2004).
27. H. Lucian, C. Monica, and N. Toshitaka, "Brain serotonin depletion impairs short-term memory, but not Long-term memory in rats", *Physiol Behav*, 91(5), 652-657 (2007).
28. J. B. Morris, and J. Janick, "Editors. Legume genetic resources with novel value added industrial and pharmaceutical use. Perspectives on New crops and New Uses", *Alexandria, VA, USA: ASHS Press, Inc*, 196-201 (1999).
29. G. L. Ellman, D. K. Courtney, V. Andres, and R. M. Featherstone, "A new and rapid colorimetric determination of acetylcholinesterase activity", *Biochem Pharmacol*, 7(2), 88-95 (1961)
30. E. D. Wills, "Mechanism of lipid peroxide formation in animals", *Biochem J*, 99(3), 667-676 (1965).

31. L. C. Green, D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum, "Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids", *Anal Biochem*, 126(1), 131-138 (1982).
32. Y. Kono, "Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase", *Arch Biochem Biophys*, 186(1), 189-195 (1978).
33. A. Claiborne, and R. A. Greenwald, editors. Catalase activity. Handbook of methods for oxygen radical research", Boca Raton: CRC Press, Inc, 283-284 (1985).
34. D. J. Jollow, J. R. Mitchell, N. Zampaglione, and J. R. Gillette, "Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite", *Pharmacology*, 11(3), 151-169 (1974).
35. A. K. Singhal, V. Naithani, and O. P. Bangar, "Medicinal plants with a potential to treat Alzheimer and associated symptoms", *Int J Nutri Pharmaco Neuro Dis*, 2(2), 84-91 (2012).
36. M. S. Uddin, M. Asaduzzaman, A. A. Mamun, M. A. Iqbal, F. Wahid, and R. Ram Kamol, "Neuroprotective Activity of *Asparagus racemosus* Linn. Against Ethanol-Induced Cognitive Impairment and Oxidative Stress in Rats Brain: Auspicious for Controlling the Risk of Alzheimer's Disease", *J Alzheimers Dis Parkinsonism*, 6(4), 245 (2016)
37. F. Babaei-Balderlou, S. Zare, R. Heidari, and F. Farrokhi, "Effects of melatonin and vitamin E on peripheral neuropathic pain in streptozotocin-induced diabetic rats", *Iran J Basic Med Sci*, 13(2), 1-8 (2010).
38. M. Tuzcu, and G. Baydas, "Effect of melatonin and vitamin E on diabetes induced learning and memory impairment in rats", *Eur J Pharmacol*, 537(1-3), 106-110 (2006).
39. R. Agrawal, E. Tyagi, R. Shukla, and C. Nath, "A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia", *Neuropharmacology*, 56(4), 779-787 (2009).
40. S. Chen, F. M. An, L. Yin, A. R. Liu, D. K. Yin, W. B. Yao, and X. D. Gao, "Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation", *Neuroscience*, 256, 137-146 (2014)
41. C. Gao, Y. Liu, Y. Jiang, J. Ding, and L. Li, "Geniposide ameliorates learning memory deficits, reduces tau phosphorylation, and decreases apoptosis via GSK-3 β pathway in streptozotocin-induced Alzheimer rat model", *Brain Pathol*, 24(3), 261-269 (2014).
42. P. K. Kamat, S. Rai, S. Swarnkar, R. Shukla, and C. Nath, "Mechanism of synapse redox stress in Okadaic acid (ICV) induced memory impairment: role of NMDA receptor", *Neurochem Int*, 76, 32-41 (2014).
43. A. R. Pathan, B. Viswanad, S. K. Sonkusare, and P. Ramarao, "Chronic administration of pioglitazone attenuates intra cerebroventricular streptozotocin induced-memory impairment in rats", *Life Sci*, 79(23), 2209-2216 (2006).
44. K. Plaschke, and S. Hoyer, "Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus", *Int J Dev Neurosci*, 11(4), 477-483 (1993).
45. M. M. Spitaler, and W. F. Graier, "Vascular targets of redox signalling in diabetes mellitus", *Diabetologia*, 45(4), 476-494 (2002).
46. G. Baydas, E. Sonkaya, M. Tuzcu, A. Yasar, and E. Donder, "Novel role for gabapentin in neuroprotection of central nervous system in streptozotocine-induced diabetic rats", *Acta Pharmacol Sin*, 26(4), 417-422 (2005)
47. K. Zare, S. R. Tabatabaei, A. Shahriari, and R. A. Jafari, "The effect of butter oil on avoidance memory in normal and diabetic rats", *Iran J Basic Med Sci*, 15(4), 983-989 (2012).



نشرة العلوم الصيدلانية جامعة أسيوط



التقييم الدوائي لنشاط منشط الذهن والوقاية العصبية لمستخلصات نباتات سيسينيا جرانديفلورا في نموذج الجرذان المصابة بمرض السكري الناجم عن الستربتوزوتوسين

جاجاديشوار كولجوري^١ - سوبهارا راجو راباكا^٢ - راشاسخار ردي الافالا^{٣*} -
كوتشوارا راو جسن^١ شيريشا بويابتي^٣ - راغافندرا كومار جوندا^٤

^١ مؤسسة كونرو لاشمايا التعليمية، فاديسوارام، جونتور، ولاية اندرا براديش، الهند، ٥٢٢٥٠٢
^٢ مدرسة شوبان براتباهاي باتيل للصيدلة وإدارة التكنولوجيا، SVKM's NMIMS، V.L. طريق ميهتا،
فيل بارلي (غرب)، مومباي، الهند، ٤٠٠٠٥٦
^٣ قسم الكيمياء الصيدلانية، جامعة تيلانجانا، نظام آباد، تيلانجانا، الهند، ٥٠٣٣٢٢
^٤ قسم العلوم الصيدلانية، مؤسسة فجنان للعلوم التكنولوجية والبحث، فادلامودي، جونتور، ولاية اندرا
براديش، الهند، ٥٢٢٢١٣

الخلفية: داء السكري (DM) هو اضطراب متعدد العوامل وغالبًا ما يرتبط بالمشاكل المزمنة المرتبطة بالأعضاء الرئيسية المختلفة. في الآونة الأخيرة، تم الإبلاغ عن بعض الارتباطات حول المضاعفات العصبية لمرض السكري، مثل ضعف الإدراك أو الخرف الوعائي أو السكتة الدماغية أو الاكتئاب. ولوحظ أن أنسجة دماغ مرضى السكري الذين يعانون من ارتفاع السكر في الدم قد أظهرت إصابة في مواقع مختلفة مع مجموعة متنوعة من التغيرات الدقيقة والبنية الكلية، مما يؤدي إلى التدهور العصبي، وتدهور الأوعية الدموية العصبية، والتهاب الأعصاب، وتدهور الإدراك التدريجي.

الهدف: تقييم الدراسة الحالية نشاط تعزيز الذاكرة لمستخلص نباتات سيسينيا جرانديفلورا (SG) في نموذج الفئران المصابة بالسكري الناجم عن الستربتوزوتوسين (STZ).

الطريقة: تم تحليل المستخلصات (الأثير البترولي، أسيتات الإيثيل والميثانول) من أجل السمية الحادة، وفيما بعد تم تحليل نشاطها الوقائي العصبي وتعزيز الذاكرة في نموذج الفئران المختار. تم إعطاء حقنة (STZ 55مجم / كجم) داخل الصفاق للحيوانات للحث على ضعف الذاكرة. تم إعطاء مستخلصات SG لمدة ٧٠ يوماً بعد تأكيد الخرف الناجم عن STZ للكشف عن تأثيره المفيد. لمعرفة وظيفة الذاكرة، خضعت الحيوانات لاختبار متاهة Y ومتاهة موريس المائية. بعد الاختبارات، تم قتل الحيوانات وتم تحليل وظيفة كولينية وتأثير ضغط الاكسدة لأنسجة المخ.

النتائج: لوحظ أن STZ تسبب في ضعف كبير في الذاكرة، والذي تم عكسه بشكل كبير بواسطة المستخلص الميثانولي بنسبة ١٠٠ و ٢٠٠ مجم / كجم. وجد أن الخلل الوظيفي الكوليني، وارتفاع مستويات بيروكسيد الدهون قد انخفض بشكل ملحوظ ($P < 0.001$) في المجموعة المصابة بمرض

السكري ، تم تحديد أن هناك انخفاضاً في أنشطة الجلوتاثيون سوبر اكسيد ديسميوتاز ، والكتلاز مقارنة بحيوانات المجموعة الضابطة.

الخلاصة: أثبتت الدراسة الحالية أن مستخلصات أوراق SG تعمل على تحسين الذاكرة عن طريق تعزيز انتقال الكولين وتقليل الاكسدة في مخ الجرذان المصابة بداء السكري.